Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

Study of Fluoxetine in Autism
Study Of Fluoxetine In Autism: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group 14-Week Study To Investigate The Effect Of Fluoxetine Orally Dissolving Tablet (ODT) On Repetitive Behaviors In Childhood And Adolescent Autistic Disorder.
Status: Enrolling
Updated:  4/26/2012
University of California-Davis
mi
from
Sacramento, CA
Study of Fluoxetine in Autism
Study Of Fluoxetine In Autism: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group 14-Week Study To Investigate The Effect Of Fluoxetine Orally Dissolving Tablet (ODT) On Repetitive Behaviors In Childhood And Adolescent Autistic Disorder.
Status: Enrolling
Updated: 4/26/2012
University of California-Davis
mi
from
Sacramento, CA
Click here to add this to my saved trials
Study of Fluoxetine in Autism
Study Of Fluoxetine In Autism: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group 14-Week Study To Investigate The Effect Of Fluoxetine Orally Dissolving Tablet (ODT) On Repetitive Behaviors In Childhood And Adolescent Autistic Disorder.
Status: Enrolling
Updated:  4/26/2012
University of Florida, Department of Psychiatry
mi
from
Gainesville, FL
Study of Fluoxetine in Autism
Study Of Fluoxetine In Autism: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group 14-Week Study To Investigate The Effect Of Fluoxetine Orally Dissolving Tablet (ODT) On Repetitive Behaviors In Childhood And Adolescent Autistic Disorder.
Status: Enrolling
Updated: 4/26/2012
University of Florida, Department of Psychiatry
mi
from
Gainesville, FL
Click here to add this to my saved trials
Study of Fluoxetine in Autism
Study Of Fluoxetine In Autism: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group 14-Week Study To Investigate The Effect Of Fluoxetine Orally Dissolving Tablet (ODT) On Repetitive Behaviors In Childhood And Adolescent Autistic Disorder.
Status: Enrolling
Updated:  4/26/2012
Institute for Behavioral Medicine
mi
from
Smyrna, GA
Study of Fluoxetine in Autism
Study Of Fluoxetine In Autism: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group 14-Week Study To Investigate The Effect Of Fluoxetine Orally Dissolving Tablet (ODT) On Repetitive Behaviors In Childhood And Adolescent Autistic Disorder.
Status: Enrolling
Updated: 4/26/2012
Institute for Behavioral Medicine
mi
from
Smyrna, GA
Click here to add this to my saved trials
Study of Fluoxetine in Autism
Study Of Fluoxetine In Autism: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group 14-Week Study To Investigate The Effect Of Fluoxetine Orally Dissolving Tablet (ODT) On Repetitive Behaviors In Childhood And Adolescent Autistic Disorder.
Status: Enrolling
Updated:  4/26/2012
Univ of Illinois
mi
from
Chicago, IL
Study of Fluoxetine in Autism
Study Of Fluoxetine In Autism: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group 14-Week Study To Investigate The Effect Of Fluoxetine Orally Dissolving Tablet (ODT) On Repetitive Behaviors In Childhood And Adolescent Autistic Disorder.
Status: Enrolling
Updated: 4/26/2012
Univ of Illinois
mi
from
Chicago, IL
Click here to add this to my saved trials
Study of Fluoxetine in Autism
Study Of Fluoxetine In Autism: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group 14-Week Study To Investigate The Effect Of Fluoxetine Orally Dissolving Tablet (ODT) On Repetitive Behaviors In Childhood And Adolescent Autistic Disorder.
Status: Enrolling
Updated:  4/26/2012
AMR Baber Research Inc.
mi
from
Naperville, IL
Study of Fluoxetine in Autism
Study Of Fluoxetine In Autism: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group 14-Week Study To Investigate The Effect Of Fluoxetine Orally Dissolving Tablet (ODT) On Repetitive Behaviors In Childhood And Adolescent Autistic Disorder.
Status: Enrolling
Updated: 4/26/2012
AMR Baber Research Inc.
mi
from
Naperville, IL
Click here to add this to my saved trials
Study of Fluoxetine in Autism
Study Of Fluoxetine In Autism: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group 14-Week Study To Investigate The Effect Of Fluoxetine Orally Dissolving Tablet (ODT) On Repetitive Behaviors In Childhood And Adolescent Autistic Disorder.
Status: Enrolling
Updated:  4/26/2012
Harvard Medical School
mi
from
Medford, MA
Study of Fluoxetine in Autism
Study Of Fluoxetine In Autism: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group 14-Week Study To Investigate The Effect Of Fluoxetine Orally Dissolving Tablet (ODT) On Repetitive Behaviors In Childhood And Adolescent Autistic Disorder.
Status: Enrolling
Updated: 4/26/2012
Harvard Medical School
mi
from
Medford, MA
Click here to add this to my saved trials
Study of Fluoxetine in Autism
Study Of Fluoxetine In Autism: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group 14-Week Study To Investigate The Effect Of Fluoxetine Orally Dissolving Tablet (ODT) On Repetitive Behaviors In Childhood And Adolescent Autistic Disorder.
Status: Enrolling
Updated:  4/26/2012
Children's Hospital of Michigan
mi
from
Detroit, MI
Study of Fluoxetine in Autism
Study Of Fluoxetine In Autism: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group 14-Week Study To Investigate The Effect Of Fluoxetine Orally Dissolving Tablet (ODT) On Repetitive Behaviors In Childhood And Adolescent Autistic Disorder.
Status: Enrolling
Updated: 4/26/2012
Children's Hospital of Michigan
mi
from
Detroit, MI
Click here to add this to my saved trials
Study of Fluoxetine in Autism
Study Of Fluoxetine In Autism: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group 14-Week Study To Investigate The Effect Of Fluoxetine Orally Dissolving Tablet (ODT) On Repetitive Behaviors In Childhood And Adolescent Autistic Disorder.
Status: Enrolling
Updated:  4/26/2012
Center for Psychiatry and Behavioral Medicine, Inc.
mi
from
Las Vegas, NV
Study of Fluoxetine in Autism
Study Of Fluoxetine In Autism: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group 14-Week Study To Investigate The Effect Of Fluoxetine Orally Dissolving Tablet (ODT) On Repetitive Behaviors In Childhood And Adolescent Autistic Disorder.
Status: Enrolling
Updated: 4/26/2012
Center for Psychiatry and Behavioral Medicine, Inc.
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Study of Fluoxetine in Autism
Study Of Fluoxetine In Autism: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group 14-Week Study To Investigate The Effect Of Fluoxetine Orally Dissolving Tablet (ODT) On Repetitive Behaviors In Childhood And Adolescent Autistic Disorder.
Status: Enrolling
Updated:  4/26/2012
CRCNJ
mi
from
Voorhees, NJ
Study of Fluoxetine in Autism
Study Of Fluoxetine In Autism: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group 14-Week Study To Investigate The Effect Of Fluoxetine Orally Dissolving Tablet (ODT) On Repetitive Behaviors In Childhood And Adolescent Autistic Disorder.
Status: Enrolling
Updated: 4/26/2012
CRCNJ
mi
from
Voorhees, NJ
Click here to add this to my saved trials
Study of Fluoxetine in Autism
Study Of Fluoxetine In Autism: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group 14-Week Study To Investigate The Effect Of Fluoxetine Orally Dissolving Tablet (ODT) On Repetitive Behaviors In Childhood And Adolescent Autistic Disorder.
Status: Enrolling
Updated:  4/26/2012
Long Island Jewish Hospital
mi
from
Bethpage, NY
Study of Fluoxetine in Autism
Study Of Fluoxetine In Autism: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group 14-Week Study To Investigate The Effect Of Fluoxetine Orally Dissolving Tablet (ODT) On Repetitive Behaviors In Childhood And Adolescent Autistic Disorder.
Status: Enrolling
Updated: 4/26/2012
Long Island Jewish Hospital
mi
from
Bethpage, NY
Click here to add this to my saved trials
Study of Fluoxetine in Autism
Study Of Fluoxetine In Autism: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group 14-Week Study To Investigate The Effect Of Fluoxetine Orally Dissolving Tablet (ODT) On Repetitive Behaviors In Childhood And Adolescent Autistic Disorder.
Status: Enrolling
Updated:  4/26/2012
Mount Sinai School of Medicine
mi
from
New York, NY
Study of Fluoxetine in Autism
Study Of Fluoxetine In Autism: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group 14-Week Study To Investigate The Effect Of Fluoxetine Orally Dissolving Tablet (ODT) On Repetitive Behaviors In Childhood And Adolescent Autistic Disorder.
Status: Enrolling
Updated: 4/26/2012
Mount Sinai School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
Study of Fluoxetine in Autism
Study Of Fluoxetine In Autism: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group 14-Week Study To Investigate The Effect Of Fluoxetine Orally Dissolving Tablet (ODT) On Repetitive Behaviors In Childhood And Adolescent Autistic Disorder.
Status: Enrolling
Updated:  4/26/2012
Univ of North Carolina
mi
from
Chapel Hill, NC
Study of Fluoxetine in Autism
Study Of Fluoxetine In Autism: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group 14-Week Study To Investigate The Effect Of Fluoxetine Orally Dissolving Tablet (ODT) On Repetitive Behaviors In Childhood And Adolescent Autistic Disorder.
Status: Enrolling
Updated: 4/26/2012
Univ of North Carolina
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Study of Fluoxetine in Autism
Study Of Fluoxetine In Autism: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group 14-Week Study To Investigate The Effect Of Fluoxetine Orally Dissolving Tablet (ODT) On Repetitive Behaviors In Childhood And Adolescent Autistic Disorder.
Status: Enrolling
Updated:  4/26/2012
Ohio State University
mi
from
Columbus, OH
Study of Fluoxetine in Autism
Study Of Fluoxetine In Autism: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group 14-Week Study To Investigate The Effect Of Fluoxetine Orally Dissolving Tablet (ODT) On Repetitive Behaviors In Childhood And Adolescent Autistic Disorder.
Status: Enrolling
Updated: 4/26/2012
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Study of Fluoxetine in Autism
Study Of Fluoxetine In Autism: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group 14-Week Study To Investigate The Effect Of Fluoxetine Orally Dissolving Tablet (ODT) On Repetitive Behaviors In Childhood And Adolescent Autistic Disorder.
Status: Enrolling
Updated:  4/26/2012
Western Psychiatric Institute and Clinic/ Merck Child Outpatient Clinic
mi
from
Pittsburgh, PA
Study of Fluoxetine in Autism
Study Of Fluoxetine In Autism: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group 14-Week Study To Investigate The Effect Of Fluoxetine Orally Dissolving Tablet (ODT) On Repetitive Behaviors In Childhood And Adolescent Autistic Disorder.
Status: Enrolling
Updated: 4/26/2012
Western Psychiatric Institute and Clinic/ Merck Child Outpatient Clinic
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Study of Fluoxetine in Autism
Study Of Fluoxetine In Autism: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group 14-Week Study To Investigate The Effect Of Fluoxetine Orally Dissolving Tablet (ODT) On Repetitive Behaviors In Childhood And Adolescent Autistic Disorder.
Status: Enrolling
Updated:  4/26/2012
Red Oak Psychiatry Associates, PA
mi
from
Houston, TX
Study of Fluoxetine in Autism
Study Of Fluoxetine In Autism: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group 14-Week Study To Investigate The Effect Of Fluoxetine Orally Dissolving Tablet (ODT) On Repetitive Behaviors In Childhood And Adolescent Autistic Disorder.
Status: Enrolling
Updated: 4/26/2012
Red Oak Psychiatry Associates, PA
mi
from
Houston, TX
Click here to add this to my saved trials
Study of Fluoxetine in Autism
Study Of Fluoxetine In Autism: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group 14-Week Study To Investigate The Effect Of Fluoxetine Orally Dissolving Tablet (ODT) On Repetitive Behaviors In Childhood And Adolescent Autistic Disorder.
Status: Enrolling
Updated:  4/26/2012
Seattle Children's Hosptial University of Washington
mi
from
Seattle, WA
Study of Fluoxetine in Autism
Study Of Fluoxetine In Autism: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group 14-Week Study To Investigate The Effect Of Fluoxetine Orally Dissolving Tablet (ODT) On Repetitive Behaviors In Childhood And Adolescent Autistic Disorder.
Status: Enrolling
Updated: 4/26/2012
Seattle Children's Hosptial University of Washington
mi
from
Seattle, WA
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
Carl T. Hayden VA Medical Center
mi
from
Phoenix, AZ
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
Carl T. Hayden VA Medical Center
mi
from
Phoenix, AZ
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
Central Arkansas VHS Eugene J. Towbin Healthcare Ctr, Little Rock
mi
from
No. Little Rock, AR
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
Central Arkansas VHS Eugene J. Towbin Healthcare Ctr, Little Rock
mi
from
No. Little Rock, AR
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
VA Medical Center, Loma Linda
mi
from
Loma Linda, CA
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
VA Medical Center, Loma Linda
mi
from
Loma Linda, CA
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
VA Palo Alto Health Care System
mi
from
Palo Alto, CA
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
VA Palo Alto Health Care System
mi
from
Palo Alto, CA
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
VA Connecticut Health Care System
mi
from
West Haven, CT
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
VA Connecticut Health Care System
mi
from
West Haven, CT
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
VA Medical Center, Bay Pines
mi
from
Bay Pines, FL
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
VA Medical Center, Bay Pines
mi
from
Bay Pines, FL
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
North Florida/South Georgia Veterans Health System
mi
from
Gainesville, FL
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
North Florida/South Georgia Veterans Health System
mi
from
Gainesville, FL
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
VA Medical Center, Miami
mi
from
Miami, FL
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
VA Medical Center, Miami
mi
from
Miami, FL
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
James A. Haley Veterans Hospital, Tampa
mi
from
Tampa, FL
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
James A. Haley Veterans Hospital, Tampa
mi
from
Tampa, FL
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
Edward Hines,Jr., VA Hospital
mi
from
Hines, IL
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
Edward Hines,Jr., VA Hospital
mi
from
Hines, IL
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
Richard Roudebush VA Medical Center, Indianapolis
mi
from
Indianapolis, IN
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
Richard Roudebush VA Medical Center, Indianapolis
mi
from
Indianapolis, IN
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
VA Medical Center, Iowa City
mi
from
Iowa City, IA
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
VA Medical Center, Iowa City
mi
from
Iowa City, IA
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
VA Maryland Health Care System, Baltimore
mi
from
Baltimore, MD
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
VA Maryland Health Care System, Baltimore
mi
from
Baltimore, MD
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
VA Medical Center, Jamaica Plain Campus
mi
from
Boston, MA
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
VA Medical Center, Jamaica Plain Campus
mi
from
Boston, MA
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
VA Medical Center, Minneapolis
mi
from
Minneapolis, MN
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
VA Medical Center, Minneapolis
mi
from
Minneapolis, MN
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
VA Medical Center, Kansas City MO
mi
from
Kansas City, MO
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
VA Medical Center, Kansas City MO
mi
from
Kansas City, MO
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
VA Medical Center, St Louis
mi
from
St Louis, MO
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
VA Medical Center, St Louis
mi
from
St Louis, MO
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
VA Medical Center, Omaha
mi
from
Omaha, NE
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
VA Medical Center, Omaha
mi
from
Omaha, NE
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
VA New Jersey Health Care System, East Orange
mi
from
East Orange, NJ
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
VA New Jersey Health Care System, East Orange
mi
from
East Orange, NJ
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
New Mexico VA Health Care System, Albuquerque
mi
from
Albuquerque, NM
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
New Mexico VA Health Care System, Albuquerque
mi
from
Albuquerque, NM
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
VA Western New York Healthcare System at Buffalo
mi
from
Buffalo, NY
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
VA Western New York Healthcare System at Buffalo
mi
from
Buffalo, NY
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
VA Medical Center, Durham
mi
from
Durham, NC
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
VA Medical Center, Durham
mi
from
Durham, NC
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
VA Medical Center, Cleveland
mi
from
Cleveland, OH
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
VA Medical Center, Cleveland
mi
from
Cleveland, OH
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
VA Medical Center, Portland
mi
from
Portland, OR
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
VA Medical Center, Portland
mi
from
Portland, OR
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
VA Pittsburgh Healthcare System
mi
from
Pittsburgh, PA
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
VA Pittsburgh Healthcare System
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
VA Pittsburgh Health Care System
mi
from
Pittsburgh, PA
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
VA Pittsburgh Health Care System
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
Ralph H Johnson VA Medical Center, Charleston
mi
from
Charleston, SC
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
Ralph H Johnson VA Medical Center, Charleston
mi
from
Charleston, SC
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
WJB Dorn Veterans Hospital, Columbia
mi
from
Columbia, SC
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
WJB Dorn Veterans Hospital, Columbia
mi
from
Columbia, SC
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
VA Medical Center, Memphis
mi
from
Memphis, TN
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
VA Medical Center, Memphis
mi
from
Memphis, TN
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
VA Medical Center
mi
from
Nashville, TN
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
VA Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
VA North Texas Health Care System, Dallas
mi
from
Dallas, TX
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
VA North Texas Health Care System, Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
Hunter Holmes McGuire VA Medical Center
mi
from
Richmond, VA
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
Hunter Holmes McGuire VA Medical Center
mi
from
Richmond, VA
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
Zablocki VA Medical Center, Milwaukee
mi
from
Milwaukee, WI
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
Zablocki VA Medical Center, Milwaukee
mi
from
Milwaukee, WI
Click here to add this to my saved trials
NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple Sclerosis Experiencing Fatigue or Sleepiness
NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Relapsing Forms of Multiple Sclerosis Experiencing Fatigue or Sleepiness
Status: Enrolling
Updated:  5/2/2012
South Shore Neurologic Associates
mi
from
Patchogue, NY
NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple Sclerosis Experiencing Fatigue or Sleepiness
NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Relapsing Forms of Multiple Sclerosis Experiencing Fatigue or Sleepiness
Status: Enrolling
Updated: 5/2/2012
South Shore Neurologic Associates
mi
from
Patchogue, NY
Click here to add this to my saved trials